CN115397425A - 使用曲匹地尔治疗认知障碍 - Google Patents

使用曲匹地尔治疗认知障碍 Download PDF

Info

Publication number
CN115397425A
CN115397425A CN202080095429.7A CN202080095429A CN115397425A CN 115397425 A CN115397425 A CN 115397425A CN 202080095429 A CN202080095429 A CN 202080095429A CN 115397425 A CN115397425 A CN 115397425A
Authority
CN
China
Prior art keywords
per day
tripidil
combination
pharmaceutically acceptable
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095429.7A
Other languages
English (en)
Chinese (zh)
Inventor
阿拉什·伯德巴尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinopia Biosciences Inc
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Publication of CN115397425A publication Critical patent/CN115397425A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080095429.7A 2019-12-02 2020-12-01 使用曲匹地尔治疗认知障碍 Pending CN115397425A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942645P 2019-12-02 2019-12-02
US62/942,645 2019-12-02
PCT/US2020/062751 WO2021113266A1 (en) 2019-12-02 2020-12-01 Treating cognitive disorders using trapidil

Publications (1)

Publication Number Publication Date
CN115397425A true CN115397425A (zh) 2022-11-25

Family

ID=76221925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095429.7A Pending CN115397425A (zh) 2019-12-02 2020-12-01 使用曲匹地尔治疗认知障碍

Country Status (7)

Country Link
US (1) US20220378794A1 (https=)
EP (1) EP4069239A4 (https=)
JP (2) JP7656608B2 (https=)
CN (1) CN115397425A (https=)
AU (1) AU2020398858B2 (https=)
CA (1) CA3163242A1 (https=)
WO (1) WO2021113266A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695338B2 (en) * 2015-05-07 2020-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
MX2022011879A (es) 2020-03-26 2023-01-11 Sinopia Biosciences Inc Derivados de trapidilo marcados isotopicamente.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02212488A (ja) * 1989-02-13 1990-08-23 Shinichiro Shimizu トリアゾールピリミジン誘導体
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
JP7049683B2 (ja) * 2016-04-04 2022-04-07 シノピア バイオサイエンシーズ,インク. トラピジルを使用する錐体外路症候群の処置
JP2021524837A (ja) * 2018-04-13 2021-09-16 ヒールクス リミテッドHealx Limited 脆弱x症候群のためのキット、組成物および併用療法

Also Published As

Publication number Publication date
CA3163242A1 (en) 2021-06-10
EP4069239A4 (en) 2023-11-29
AU2020398858B2 (en) 2026-02-19
AU2020398858A1 (en) 2022-06-30
WO2021113266A1 (en) 2021-06-10
JP7656608B2 (ja) 2025-04-03
JP2025111439A (ja) 2025-07-30
EP4069239A1 (en) 2022-10-12
JP2023504004A (ja) 2023-02-01
US20220378794A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US20180311153A1 (en) Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US12268691B2 (en) Treating extrapyramidal syndrome using trapidil
US20240058353A1 (en) Methods for treating gi tract disorders
TW201605455A (zh) Bet抑制劑與布魯頓氏酪胺酸激酶抑制劑之組合
JP2025111439A (ja) トラピジルを使用した認知障害の治療
US20190111059A1 (en) Compositions and methods for treating autism spectrum disorder
WO2017011314A1 (en) Btk and hdac combinations
US20170360805A1 (en) Motor-associated neurodegenerative disease and methods of treatment
HK40004660A (en) Treating levodopa-induced dyskinesia using trapidil

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination